登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由福建省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07836257,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer.
入选标准第 2 条
HER2-positive status confirmed by a central laboratory or the institutional pathology department according to the current ASCO/CAP guidelines, defined as immunohistochemistry (IHC) 3+ or in situ hybridization (ISH) positive.
入选标准第 3 条
Prior treatment with T-DXd in the second-line or later setting, with radiologically documented disease progression during or after T-DXd therapy according to RECIST v1.1.
入选标准第 4 条
Patients with brain metastases are eligible if the metastases are untreated and do not require immediate local therapy, or if previously treated with local therapy (e.g., radiotherapy, surgery) with a washout period of at least 4 weeks.
入选标准第 6 条
Chemotherapy, other targeted therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of study treatment.
排除标准第 8 条
Participation in another interventional clinical study within 4 weeks, or within 5 half-lives of the investigational product (whichever is shorter), prior to the first dose of study treatment.
排除标准第 9 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
入选标准第 7 条
At least one measurable lesion according to RECIST v1.1.
入选标准第 5 条
Known human immunodeficiency virus (HIV) infection, or untreated active hepatitis B (HBsAg positive with HBV DNA > 500 IU/mL) or hepatitis C (HCV antibody positive with HCV RNA above the lower limit of quantification).
排除标准第 6 条
Women of childbearing potential must agree to use highly effective contraception during the study and for 7 months after the last dose; men must agree to use highly effective contraception during the study and for 4 months after the last dose. Serum or urine pregnancy test must be negative within 7 days before enrollment.
入选标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07836257,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily signed written informed consent; age ≥ 18 years; either sex. Histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer. HER2-positive status confirmed by a central laboratory or the institutional pathology department according to the current ASCO/CAP guidelines, defined as immunohistochemistry (IHC) 3+ or in situ hybridization (ISH) positive. Prior treatment with T-DXd in the second-line or later setting, with radiologically documented disease progression during or after T-DXd therapy according to RECIST v1.1. At least one measurable lesion according to RECIST v1.1. Patients with brain metastases are eligible if the metastases are untreated and do not require immediate local therapy, or if previously treated with local therapy (e.g., radiotherapy, surgery) with a washout period of at least 4 weeks. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Life expectancy of at least 3 months. Adequate organ function as defined below, without transfusion or hematopoietic growth factor support within 14 days prior to the first dose: Women of childbearing potential must agree to use highly effective contraception during the study and for 7 months after the last dose; men must agree to use highly effective contraception during the study and for 4 months after the last dose. Serum or urine pregnancy test must be negative within 7 days before enrollment.排除标准:Exclusion Criteria:
History of severe hypersensitivity to the study drugs (T-DXd, pyrotinib) or to any of their excipients. Patients with brain metastases meeting any of the following: clinically significant central nervous system symptoms requiring continuous corticosteroid or anticonvulsant therapy to control symptoms; brain metastases assessed as requiring immediate local therapy; poorly controlled (more than 1 week) generalized or complex partial seizures. History of clinically significant pulmonary disease, including but not limited to: any history of interstitial lung disease (ILD) or pneumonitis requiring steroid treatment; current active ILD/pneumonitis, or suspected ILD/pneumonitis on screening imaging that cannot be excluded. Clinically significant cardiovascular disease, including but not limited to: acute myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within 6 months prior to screening; clinically uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg); New York Heart Association (NYHA) class III or higher heart failure; QTc prolongation with QTcF > 470 ms using Fridericia's correction. Severe or uncontrolled systemic disease that, in the investigator's judgment, would compromise protocol compliance or safety assessment, such as active infection or poorly controlled diabetes mellitus. Known human immunodeficiency virus (HIV) infection, or untreated active hepatitis B (HBsAg positive with HBV DNA > 500 IU/mL) or hepatitis C (HCV antibody positive with HCV RNA above the lower limit of quantification). Major surgery or significant unhealed trauma within 4 weeks prior to the first dose of study treatment. Chemotherapy, other targeted therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of study treatment. Participation in another interventional clinical study within 4 weeks, or within 5 half-lives of the investigational product (whichever is shorter), prior to the first dose of study treatment. Chronic diarrhea, malabsorption syndrome, or other gastrointestinal disorder that may affect the absorption of orally administered medication.
引自 ClinicalTrials.gov, NCT07836257, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07836257,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。